Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (May 2015)

23 slides from Enumeral Biomedical's investor presentation, May 18, 2015

  1. Slide 1: The Power of Human

    THE POWEF Way 2015 ENUSXERAL

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUC

  3. Slide 3: Enumeral Investment Opportunity

    EnumeralInvestment Opportunity 3 A biopharma company developing potential ‘best- in-class’ antibodies against both proven and new targets using a proprietary immuno-oncology profiling technology.

  4. Slide 4: Enumeral Overview

    EnumeralOverview 4 Initial goal: develop best-in-class PD-1 antibody • Opportunity: higher initial response rates and treatment of refractory cancers • First clinical trial targeted for 2016; results expected 2017 Ability to potentially develop multiple best-in-class antibodies through ‘Human immune

  5. Slide 5: Enumeral's Differentiated Approach

    Enumeral’sDifferentiated Approach 5 Create broad antibody diversity Measure antibody function using our ‘Human immune system on a chip’ platform Select best-in-class candidates that modulate desired immune effector cells

  6. Slide 6: Enumeral Origins

    EnumeralOrigins 6 July 2014December 2009 Completed reverse merger transaction; gross proceeds of $21.5M through private placement offering, began public trading on the OTC Markets (OTCQB:ENUM) Exclusive patent license with MIT Company incorporated First equity financing closed April 2011 June 2011 “

  7. Slide 7: Experienced Leadership Team

    Experienced Leadership Team 7 John J. Rydzewski ExecutiveChairman, Co-Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co-Founder, Director CokeyNguyen, Ph.D. Vice President,Research&Development Isabel Chiu, Ph.D. Vice President, Translational& Clinical Sciences Kevin G. Sarney Vice

  8. Slide 8: Accomplished Board of Directors

    Accomplished Board of Directors 8 John J. Rydzewski ExecutiveChairman, Co-Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co-Founder, Director BarryBuckland, Ph.D. Co-Founder, Chairman, Scientific Advisory Board Allan Rothstein Director PaulJ. Sekhri Director Robert L. Van Nostrand

  9. Slide 9: Immunotherapy Market Opportunity

    Immunotherapy Market Opportunity 9 *Citigroup **Bristol Myers Squibb Estimated sales of first- in-class products over next decade $35 billion per year (treating up to 60% of cancers*) Yervoy sales (launched in 2011) $1 billion in revenue (year ended June 20, 2014**) Strong interest in new approaches

  10. Slide 10: Enumeral's Pipeline

    10 Enumeral’sPipeline 2015 2016 2017 Target Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 PD-1 Tim3 Lag-3 OX40 VISTA Undisclosed Screening Screening Screening Screening PreclinicalEfficacy Preclinical Efficacy Preclinical Efficacy Preclinical Efficacy Preclinical Efficacy IND EnablingStudies & CMC IND Enabling S

  11. Slide 11: Breaking the "Immuno-Oncology Code"

    Breaking the “Immuno-Oncology Code” Proprietary ‘humanimmune system on a chip’ selects best-in-class antibodies and optimal target combinations 11 • Developing pipeline of antibody product candidates modulating Tumor- Infiltrating Lymphocyte (TIL) function • Next-generation checkpoint modulators der

  12. Slide 12: Validation of Technology Platform

    Validation of Technology Platform* 12 *Publications from laboratory of scientific founder, J. Christopher Love, Ph.D.

  13. Slide 13: Recognition of Enumeral's Approach

    Recognition of Enumeral’sApproach • Merck: collaboration with leading immuno-oncology pharmaceutical company – Focused on using Enumeral'splatform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cellular responses to therapies being developed by Merck –

  14. Slide 14: Enumeral's Approach to T Cell-selective Antibody Discovery: PICTURE

    Enumeral’sApproach to T Cell-selective Antibody Discovery: PICTURE TM* 14 *Patent pending PICTURE: Precision Immune Cell Targeting Using Real-time Enumeration Effector T cells Hypothetical output of platform*: Antibodies selective for T cells

  15. Slide 15: Functional Diversity: Potential for Best-in-Class Differentiation

    Functional Diversity: Potential for Best-in-Class Pharmacologic and MOA Differentiation 15 Screen 1-12 Heavy chain AA sequences from PD1 N= 349 sequences; 28 families of antibodies OPDIVO® KEYTRUDA® Pidilizumab • Enumeral proprietary antibody libraries - unprecedented functional diversity • PD-1: ~1

  16. Slide 16: Platform Enables Identification of Antibodies That Selectively Modulate T Cells

    Platform Enables Identification of Antibodies That Selectively Modulate T Cells 16 Biopsy from colorectal cancer patient; No sorting or enrichment • Preclinical animal models poorly developed • Enumeral‘human immune system on a chip’ enables us to measure the effect our antibody candidates have on i

  17. Slide 17: Enumeral's Broadly Enabling Platform

    Enumeral’s Broadly Enabling Platform 17 84,672 microwells • High-density bio-chip and one-day process • Measures key parameters of function of individual immune cells from patient samples • Uniquely enumerates and rapidly identifies rare immune cellscritical to responses • Validates targets and effi

  18. Slide 18: ENUM Antibodies Demonstrate pM Affinity

    ENUM Antibodies Demonstrate pMAffinity mAb EC 50 246A10 0.020 244C8 0.005 388D4 0.003 413Ec1 0.013 413D2 0.005 392C5 0.015 Keytruda 0.066 18 Several ENUM mAbs show superior EC 50 vs Keytruda (*Data Provided From Internal Enumeral Tests) 0 0.5 1 1.5 2 2.5 3 3.5 a b s ( 4 0 5 n m ) mAbconcentration (M

  19. Slide 19: PD-L1 Suppression Assay

    PD-L1 Suppression Assay 19 • PBMC-based assay to determine mAb’s ability to disrupt functional suppression by PD-L1 • ENUM candidates compared with: – Activation only – PD-L1 (suppression) – Positive control • ENUM A10 and C8 shown to reverse PD- L1 suppression more effectively than control I F N g

  20. Slide 20: PD-1 Target Physiology: Potential Beyond Oncology

    PD-1 Target Physiology: Potential to Solve Questions Based on Ex Vivo Human Profiling • Are psoriasis, inflammatory bowel disease, or rheumatoid arthritis T cell diseases? • Is the (presumed) IL-17 or IFN coming from pathologic T cells? • Is the disease etiology universal or variable across patients

  21. Slide 21: Value Creation

    Value Creation 21 Value 2012 2013 2014 2015 2016 2017 Enumeralbelieves it is well-positioned to achieve significant value-generating milestones xNCI Phase 1 contract x$21.5M financing and public listing xNCI Phase 2 contract xMerck Collaboration xMSKCC and MGH collaborations Initiate IND-enabling st

  22. Slide 22: Financials & Capitalization

    Financials & Capitalization Common Shares Outstanding 51,607,665 Warrants Outstanding* 24,803,409 Options Outstanding** 2,730,963 Burn Rate, Q1 ’15 ($2.5M) Total Debt $0.0M Cash, Cash Equivalents and Marketable Securities** $11.0M 22 OTC QB: ENUM Price: $0.65 Market Cap (5/15/2015) $34.58M *21,549,5

  23. Slide 23: The Power of Human

    THE POWER ofHUMAN™ Arthur H. Tinkelenberg, Ph.D. President and CEO arthur@enumeral.com 617-500-2647

Enumeral Biomedical Holdings — Investor Presentation (May 2015) on 6ix